The biopharmaceutical industry is currently navigating through turbulent waters as a series of layoffs and strategic overhauls ripple across the sector. The urgency that once underscored the COVID-19 pandemic has given way to a new reality where pharmaceutical giants are reassessing their
BioNTech, the German biotechnology company known for its pivotal role in creating a COVID-19 vaccine with Pfizer, has inaugurated a state-of-the-art modular mRNA vaccine production facility in Kigali, the capital of Rwanda. This initiative marks a significant step toward health equality and local
Eli Lilly is making a significant move to fortify its global network for manufacturing parenteral products by acquiring a facility from Nexus Pharmaceuticals. This strategic step is set to greatly enhance Lilly's ability to supply its growing number of medications and underscores a commitment
Under the insightful leadership of executives like Raje, LGM Pharma has experienced significant evolution since being acquired by New Harbour Capital Private Equity. Initially, LGM Pharma was primarily focused on supply chain logistics within the pharmaceutical industry. However, it has since
Ireland's biopharmaceutical industry is on the verge of substantial expansion, with an expected increase of 21,000 jobs by 2027. The Expert Group on Future Skills Needs (EGFSN) has highlighted the essential role of the biopharma sector in bolstering the national economy. Despite the optimistic
As environmental issues become ever more pressing, pharmaceutical giant Boehringer Ingelheim is leading a green revolution within its industry, with a special focus on sustainable vaccine production. The company's innovative initiatives extend well beyond the finished vaccine. Boehringer
